Wallentin, Lars

Dabigatran versus warfarin in patients with atrial fibrillation

Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine

Atrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and Management

Cited by 11,215

Apixaban versus warfarin in patients with atrial fibrillation

Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine

Atrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and Management

Cited by 8,943

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine

Antiplatelet Therapy and Cardiovascular DiseasesAcute Myocardial Infarction Research

Cited by 7,117

Large-scale association analysis identifies new risk loci for coronary artery disease

The CARDIoGRAMplusC4D Consortium, Deloukas, P., DIAGRAM Consortium, CARDIOGENICS Consortium, MuTHER Consortium, Wellcome Trust Case Control Consortium, Kanoni, S., Willenborg, C., Farrall, M., Assimes, T. L., et al. (2013) · Nature Genetics

Genetic Associations and EpidemiologyGenetic Mapping and Diversity in Plants and Animals

Cited by 1,614

Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial

Eikelboom, J. W., Wallentin, L., Connolly, S. J., Ezekowitz, M., Healey, J. S., Oldgren, J., Yang, S., Alings, M., Kaatz, S., Hohnloser, S. H., et al. (2011) · Circulation

Atrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and Management

Cited by 1,081

Common variants associated with plasma triglycerides and risk for coronary artery disease

Do, R., Willer, C. J., Schmidt, E. M., Sengupta, S., Gao, C., Peloso, G. M., Gustafsson, S., Kanoni, S., Ganna, A., Chen, J., et al. (2013) · Nature Genetics

Genetic Associations and EpidemiologyLipoproteins and Cardiovascular Health

Cited by 862

Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals

Folkersen, L., Gustafsson, S., Wang, Q., Hansen, D. H., Hedman, Å. K., Schork, A., Page, K., Zhernakova, D. V., Wu, Y., Peters, J., et al. (2020) · Nature Metabolism

Genetic Associations and EpidemiologyGenetic Mapping and Diversity in Plants and Animals

Cited by 705

Newly identified events in the RE-LY trial

Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Reilly, P. A., & Wallentin, L. (2010) · New England Journal of Medicine

Antiplatelet Therapy and Cardiovascular DiseasesAtrial Fibrillation Management and Outcomes

Cited by 688

Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial

Hohnloser, S. H., Hijazi, Z., Thomas, L., Alexander, J. H., Amerena, J., Hanna, M., Keltai, M., Lanas, F., Lopes, R. D., Lopez-Sendon, J., et al. (2012) · European Heart Journal

Atrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and Management

Cited by 574

Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease

Zanoni, P., Khetarpal, S. A., Larach, D. B., Hancock-Cerutti, W. F., Millar, J. S., Cuchel, M., DerOhannessian, S., Kontush, A., Surendran, P., Saleheen, D., et al. (2016) · Science

Cholesterol and Lipid MetabolismLipoproteins and Cardiovascular Health

Cited by 545

The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study

Hijazi, Z., Oldgren, J., Lindbäck, J., Alexander, J. H., Connolly, S. J., Eikelboom, J. W., Ezekowitz, M. D., Held, C., Hylek, E. M., Lopes, R. D., et al. (2016) · The Lancet

Atrial Fibrillation Management and OutcomesInflammatory Biomarkers in Disease Prognosis

Cited by 490

Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial

Dans, A. L., Connolly, S. J., Wallentin, L., Yang, S., Nakamya, J., Brueckmann, M., Ezekowitz, M., Oldgren, J., Eikelboom, J. W., Reilly, P. A., et al. (2013) · Circulation

Atrial Fibrillation Management and OutcomesAntiplatelet Therapy and Cardiovascular Diseases

Cited by 484

Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial

Diener, H.-C., Connolly, S. J., Ezekowitz, M. D., Wallentin, L., Reilly, P. A., Yang, S., Xavier, D., Di Pasquale, G., & Yusuf, S. (2010) · The Lancet Neurology

Atrial Fibrillation Management and OutcomesAcute Ischemic Stroke Management

Cited by 451

Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial

James, S., Angiolillo, D. J., Cornel, J. H., Erlinge, D., Husted, S., Kontny, F., Maya, J., Nicolau, J. C., Spinar, J., Storey, R. F., et al. (2010) · European Heart Journal

Antiplatelet Therapy and Cardiovascular DiseasesCoronary Interventions and Diagnostics

Cited by 446

Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995-2014

Szummer, K., Wallentin, L., Lindhagen, L., Alfredsson, J., Erlinge, D., Held, C., James, S., Kellerth, T., Lindahl, B., Ravn-Fischer, A., et al. (2017) · European Heart Journal

Acute Myocardial Infarction ResearchCoronary Interventions and Diagnostics

Cited by 443

The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation

Hijazi, Z., Lindbäck, J., Alexander, J. H., Hanna, M., Held, C., Hylek, E. M., Lopes, R. D., Oldgren, J., Siegbahn, A., Stewart, R. A. H., et al. (2016) · European Heart Journal

Atrial Fibrillation Management and OutcomesAcute Ischemic Stroke Management

Cited by 437

Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial

Mahaffey, K. W., Wojdyla, D. M., Carroll, K., Becker, R. C., Storey, R. F., Angiolillo, D. J., Held, C., Cannon, C. P., James, S., Pieper, K. S., et al. (2011) · Circulation

Antiplatelet Therapy and Cardiovascular DiseasesAcute Myocardial Infarction Research

Cited by 434

Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy

Hijazi, Z., Oldgren, J., Andersson, U., Connolly, S. J., Ezekowitz, M. D., Hohnloser, S. H., Reilly, P. A., Vinereanu, D., Siegbahn, A., Yusuf, S., et al. (2012) · Circulation

Atrial Fibrillation Management and OutcomesHeart Failure Treatment and Management

Cited by 402

Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis

Hijazi, Z., Hohnloser, S. H., Oldgren, J., Andersson, U., Connolly, S. J., Eikelboom, J. W., Ezekowitz, M. D., Reilly, P. A., Siegbahn, A., Yusuf, S., et al. (2014) · Circulation

Atrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and Management

Cited by 396

Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin

Hylek, E. M., Held, C., Alexander, J. H., Lopes, R. D., De Caterina, R., Wojdyla, D. M., Huber, K., Jansky, P., Steg, P. G., Hanna, M., et al. (2014) · Journal of the American College of Cardiology

Atrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and Management

Cited by 344

Causes of Death and Influencing Factors in Patients With Atrial Fibrillation: A Competing-Risk Analysis From the Randomized Evaluation of Long-Term Anticoagulant Therapy Study

Marijon, E., Le Heuzey, J.-Y., Connolly, S., Yang, S., Pogue, J., Brueckmann, M., Eikelboom, J., Themeles, E., Ezekowitz, M., Wallentin, L., et al. (2013) · Circulation

Atrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and Management

Cited by 314

Biomarkers in atrial fibrillation: a clinical review

Hijazi, Z., Oldgren, J., Siegbahn, A., Granger, C. B., & Wallentin, L. (2013) · European Heart Journal

Atrial Fibrillation Management and OutcomesInflammatory Biomarkers in Disease Prognosis

Cited by 298

N-Terminal Pro–B-Type Natriuretic Peptide for Risk Assessment in Patients With Atrial Fibrillation

Hijazi, Z., Wallentin, L., Siegbahn, A., Andersson, U., Christersson, C., Ezekowitz, J., Gersh, B. J., Hanna, M., Hohnloser, S., Horowitz, J., et al. (2013) · Journal of the American College of Cardiology

Atrial Fibrillation Management and OutcomesHeart Failure Treatment and Management

Cited by 231

Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo

Erlinge, D., Varenhorst, C., Braun, O. Ö., James, S., Winters, K. J., Jakubowski, J. A., Brandt, J. T., Sugidachi, A., Siegbahn, A., & Wallentin, L. (2008) · Journal of the American College of Cardiology

Antiplatelet Therapy and Cardiovascular DiseasesPlatelet Disorders and Treatments

Cited by 215